Drugs / Cellular therapy product
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03939585 | Dec 2024 → Jun 2025 | acute leukemia, disease related to hematopoietic stem cell transplant, lymphoproliferative syndrome, myelodysplastic syndrome +1 | Leland Metheny | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cellular therapy product | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03939585 ↗ |
| Modality | Cell therapy | “Cellular therapy product: Allogeneic transplant donor lymphocytes, depleted of TCR-αβ T cells and B cells; enriched for NK cells and TCRγδ T cells.” NCT03939585 ↗ |
| Route | Intravenous | “Infused using venous catheter on post-transplant Day 28 (+ 7 days).” NCT03939585 ↗ |